15-Deoxy-Δ12,14-prostaglandin J2 inhibits the expression of proinflammatory genes in human blood monocytes via a PPAR-γ-independent mechanism

被引:60
|
作者
Hinz, B [1 ]
Brune, K [1 ]
Pahl, A [1 ]
机构
[1] Univ Erlangen Nurnberg, Dept Expt & Clin Pharmacol & Toxicol, D-91054 Erlangen, Germany
关键词
peroxisome proliferator-activated receptor-gamma; 15-deoxy-Delta(12,14)-prostaglandin J(2); ciglitazone; cyclooxygenase-2; proinflammatory cytokines; human blood monocytes;
D O I
10.1016/S0006-291X(03)00195-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) has been implicated in inhibition of the expression of proinflammatory cytokines and inducible enzymes such as cyclooxygenase-2 (COX-2). Using real-time RT-PCR the present study investigates the impact of two PPAR-gamma agonists, 15-deoxy-Delta(12,14) -prostaglandin J(2) (15d-PGJ(2)) and ciglitazone, on the expression of several proinflammatory genes in lipopolysaccharide (LPS)-stimulated human blood monocytes. Stimulation of cells with LPS resulted in a profound induction of the expression of COX-2, interleukin (IL)-1, IL-6, tumor necrosis factor (TNF), and granulocyte-macrophage colony-stimulating factor (GM-CSF). Treatment of cells with 15d-PGJ(2) (10 muM) was associated with a nearly complete inhibition of the expression of all genes that remained unaltered in the presence of the PPAR-gamma antagonist bisphenol A diglycidyl ether (BADGE; 100 muM). By contrast, treatment of cells with another potent PPAR-gamma agonist, ciglitazone (50 muM), and the PPAR-alpha agonist WY-14,643 (100 muM) did not suppress LPS-induced expression of the investigated genes. Stimulation of monocytes with LPS resulted in an 88% inhibition of PPAR-gamma mRNA expression that was fully restored by 15d-PGJ(2), but only to a partial extent by ciglitazone and WY-14,643. Again, BADGE did not alter the effect of 15d-PGJ(2). Collectively, our results show that alterations of gene expression by 15d-PGJ(2), in LPS-stimulated human blood monocytes are mediated by PPAR-gamma-independent mechanisms. Moreover, it is concluded that both inhibition of proinflammatory gene expression and restoration of LPS-induced decrease of PPAR-gamma expression may contribute to the biological action of 15d-PGJ(2). (C) 2003 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:415 / 420
页数:6
相关论文
共 50 条
  • [41] The cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 ameliorates ischemic acute renal failure
    Chatterjee, PK
    Patel, NSA
    Cuzzocrea, S
    Brown, PAJ
    Stewart, KN
    Mota-Filipe, H
    Britti, D
    Eberhardt, W
    Pfeilschifter, J
    Thiemermann, C
    [J]. CARDIOVASCULAR RESEARCH, 2004, 61 (03) : 630 - 643
  • [42] Detection of 15-deoxy-Δ12,14-prostaglandin J2 in smooth muscle cells in human atherosclerotic aorta
    Toi, S
    Shibata, N
    Uchida, K
    Uchiyama, S
    Sakayori, N
    Muramatsu, F
    Kawaguchi, M
    Sawada, T
    Kobayashi, M
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (02) : 209 - 209
  • [43] 15-Deoxy-Δ12,14-prostaglandin J2 inhibits IL-10 and IL-12 production by macrophages
    Azuma, Y
    Shinohara, R
    Wang, PL
    Ohura, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 283 (02) : 344 - 346
  • [44] 15-deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway
    Straus, DS
    Pascual, G
    Li, M
    Welch, JS
    Ricote, M
    Hsiang, CH
    Sengchanthalangsy, LL
    Ghosh, G
    Glass, CK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (09) : 4844 - 4849
  • [45] The cyclopentenone prostaglandin 15-deoxy-Δ12,14-prostaglandin J2 attenuates the development of acute and chronic inflammation
    Cuzzocrea, S
    Wayman, NS
    Mazzon, E
    Dugo, L
    Di Paola, R
    Serraino, I
    Britti, D
    Chatterjee, PK
    Caputi, AP
    Thiemermann, C
    [J]. MOLECULAR PHARMACOLOGY, 2002, 61 (05) : 997 - 1007
  • [46] Suppression of bleomycin-induced lung fibrosis by 15-deoxy-Δ12,14-prostaglandin J2
    Hayashi, I
    Ando, M
    Endo, H
    Kitasato, H
    Majima, M
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 246P - 246P
  • [47] The mitochondrial respiratory complex I is a target for 15-deoxy-Δ12,14-prostaglandin J2 action
    Martinez, B
    Pérez-Castillo, A
    Santos, A
    [J]. JOURNAL OF LIPID RESEARCH, 2005, 46 (04) : 736 - 743
  • [48] Feedback control of the arachidonate cascade in osteoblastic cells by 15-deoxy-Δ12,14-prostaglandin J2
    Ishino, Hidetaka
    Kawahito, Yutaka
    Tsubouchi, Yasunori
    Kohno, Masataka
    Wada, Makoto
    Yamamoto, Aihiro
    Hamaguchi, Masahide
    Kadoya, Masatoshi
    Tokunaga, Daisaku
    Hojo, Tatsuya
    Matsuyama, Masahide
    Yoshimura, Rikio
    Yoshikawa, Toshikazu
    [J]. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 2008, 42 (01) : 64 - 69
  • [49] 15-Deoxy-Δ12,14-prostaglandin J2 induced neurotoxicity via suppressing phosphoinositide 3-kinase
    Koma, Hiromi
    Yamamoto, Yasuhiro
    Nishii, Ayaka
    Yagami, Tatsurou
    [J]. NEUROPHARMACOLOGY, 2017, 113 : 416 - 425
  • [50] 15-Deoxy-Δ12,14-prostaglandin J2 inhibits IL-1β-induced cyclooxygenase-2 expression in mesangial cells
    Sawano, H
    Haneda, M
    Sugimoto, T
    Inoki, K
    Koya, D
    Kikkawa, R
    [J]. KIDNEY INTERNATIONAL, 2002, 61 (06) : 1957 - 1967